Please assess the completion status of the following clinical trial:

Trial Title: Microvascular Coronary Disease In Women: Impact Of Ranolazine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Women with signs and symptoms of myocardial ischemia (chest pain, abnormal stress testing, abnormal noninvasive testing) in the absence of obstructive coronary artery disease (epicardial coronary stenosis \<50% luminal diameter stenosis).~2. Women with ≥10% myocardial ischemia by CMR perfusion.~Exclusion Criteria:~1. Contraindications to withholding nitrates, beta-blockers, calcium channel agents, ACE/ARB agents for 48 hours prior to testing.~2. Contraindications in CMR including AICD, pacemaker, untreatable claustrophobia or known angio-edema.~3. Contraindications to ranolazine including hepatic insufficiency, prolonged QT, renal failure.~4. Women taking drugs that inhibit CYP3A such as diltiazem, verapamil, ketoconazole, macrolides or HIV protease inhibitors.~5. Women less than 18 years of age.~6. Women on drugs that prolong the QT interval such as Class Ia or III antiarrhythmic agents, erythromycin, certain antipsychotics.~7. Pregnancy or breast feeding.~8. Life expectancy less than 6 months.

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Study Drug Ranexa, Then Placebo (Type: EXPERIMENTAL): Participants first received study drug Ranexa, 500mg, orally twice daily for 2 weeks, assuming tolerance, followed by 1000mg orally twice daily for an additional 2 weeks. If the participant is unable to increase dose secondary to side effects, she will remain on 500mg twice daily for the second 2-week interval.~After a washout period of 2 weeks, they then received Placebo tablet (matching Ranexa tablet).
- Placebo, Then Study Drug Ranexa(Ranolazine) (Type: EXPERIMENTAL): Participants first received Placebo tablet (matching Ranexa tablet) for two weeks.~After washout period of 2 weeks, they then received Ranexa 500mg, orally twice daily for 2 weeks, assuming tolerance, followed by 1000mg orally twice daily for an additional 2 weeks. If the participant is unable to increase dose secondary to side effects, she will remain on 500mg twice daily for the second 2-week interval.

Based on this trial design, predict the completion outcome and termination type (if applicable).